Eiken Pia A, Vestergaard Peter
Kardiologisk, Nefrologisk, Endokrinologisk Afdeling H 0652, Nordsjællands Hospital Hillerød, Dyrehavevej 29, 3400 Hillerød.
Ugeskr Laeger. 2015 Aug 31;177(36).
One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.
50岁以上的男性中，五分之一的人在一生中会遭受骨质疏松性骨折，与女性相比，发生骨折的男性死亡风险更高。目前丹麦已批准三种双膦酸盐（阿仑膦酸钠、利塞膦酸钠和唑来膦酸）、地诺单抗、雷奈酸锶和特立帕肽用于治疗男性骨质疏松症。本综述总结了现有的治疗选择。
